

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 879 228 B1

94

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:

30.10.2002 Bulletin 2002/44

(51) Int Cl.7: **C07D 211/34**

(86) International application number:
PCT/GB97/00281

(21) Application number: **97902435.3**

(87) International publication number:
WO 97/028124 (07.08.1997 Gazette 1997/34)

(22) Date of filing: **31.01.1997**

(54) **PROCESS FOR THE PREPARATION OF D-THREO-(R,R)-METHYL PHENIDATE AND RECYCLING OF UNDESIRE ENANTIOMERS BY EPIMERISATION**

**VERFAHREN ZUR HERSTELLUNG VON D-THREO-(R,R)-METHYLPHENIDAT UND RECYCLING
NICHT ERWÜNSCHTER ENANTIOMERE DURCH EPIMERISIERUNG**

**PROCEDE DE PREPARATION DE D-THREO-(R,R)-METHYLPHENIDATE ET DE RECYCLAGE
D'ENANTIOMERES INDESIRABLES PAR EPIMERISATION**

(84) Designated Contracting States:
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE**

(30) Priority: **02.02.1996 GB 9602174**
10.09.1996 GB 9618836

(43) Date of publication of application:
25.11.1998 Bulletin 1998/48

(73) Proprietor: **MEDEVA EUROPE LIMITED**
Slough Berks SL1 3WE (GB)

(72) Inventors:
• **LANGSTON, Marianne Chiroscience Limited**
Cambridge CB4 4WE (GB)
• **ZAVAREH, Hooshang, Shahriari**
Chiroscience Limited
Cambridge CB4 4WE (GB)

(74) Representative: **Perry, Robert Edward**
GILL JENNINGS & EVERY
Broadgate House
7 Eldon Street
London EC2M 7LH (GB)

(56) References cited:
US-A- 2 957 880

- **J. ORG. CHEM.**, vol. 48, no. 6, 1983, pages 843-846, XP000604702 S. YAMADA ET AL.: "Method for the Racemization of Optically Active Amino Acids"
- **CHEMICAL ABSTRACTS**, vol. 107, no. 3, 20 July 1987 Columbus, Ohio, US; abstract no. 17704, PATRICK, KENNERLY S. ET AL: "Pharmacology of the enantiomers of threo-methylphenidate" XP002029010 cited in the application & J. PHARMACOL. EXP. THER. (1987), 241(1), 152-8 CODEN: JPETAB;ISSN: 0022-3565, 1987,
- **CHEMICAL ABSTRACTS**, vol. 83, no. 13, 29 September 1975 Columbus, Ohio, US; abstract no. 114219, YAKHONTOV, L. N. ET AL: "Methyl threo-.alpha.-phenyl-.alpha.-(2-piperidyl) acetate hydrochloride" XP002029011 & SU 466 229 A (ORDZHONIKIDZE, S., ALL-UNION SCIENTIFIC-RESEARCH CHEMICAL-PHARMACEUTI)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 879 228 B1

DescriptionField of the Invention

5 [0001] This invention relates to an economic process for the manufacture of a single isomer of methylphenidate.

Background to the Invention

10 [0002] Methylphenidate is a therapeutic agent that is widely used in the treatment of attention-deficit hyperactivity disorder. It is a controlled substance.

[0003] Methylphenidate was first prepared as a mixture of the *erythro* [*R***S**] and *threo* [*R***R**] racemates. US-A-2957880 discloses studies upon the two racemic mixtures, which revealed that the therapeutic activity resides in the *threo* diastereoisomer. It is now considered that it is the *d-threo* [or (*R,R*)] enantiomer that has the preferred therapeutic activity. Uses of this enantiomer are disclosed in PCT/GB96/01688, PCT/GB96/01689 and PCT/GB96/01690, the contents of which are incorporated herein by reference.


15 [0004] The resolution of *threo*-methylphenidate can be achieved using the expensive resolving agent 1,1'-binaphthyl-2,2'-diyl hydrogen phosphate, a process first reported by Patrick *et al*, The Journal of Pharmacology and Experimental Therapeutics, 241:152-158 (1987). A more efficient resolution, using a *O,O'*-diaroyltartaric acid, is disclosed in PCT/GB97/00185, the contents of which are incorporated by reference; in particular, the use *O,O'*-di-*p*-toluoyltartaric acid
20 allows the diastereoisomeric salts to be very readily separated.

[0005] In an alternative approach, disclosed in US-A-2957880, the amide of *erythromethylphenidate* (i.e. as -CONH₂ instead of -CO₂Me) is resolved using tartaric acid. However, this resolution must be followed by amide hydrolysis, and equilibration at the benzylic centre, to give the *threo* isomer of the carboxylic acid (ritalinic acid) which is esterified. US-A-2957880 describes a general process for conversion of *erythro* diastereoisomers to *threo* diastereoisomers,
25 using alkali and elevated temperature.

[0006] In order to establish an economic resolution process, it is highly desirable to be able to recycle the unwanted enantiomer into the resolution by way of a racemisation. This becomes especially important when the resolution is performed late in a synthesis. An example of such a resolution and racemisation procedure is in the case of naproxen where the single stereogenic carbon centre, which is benzylic and further activated by the carboxylate, is readily racemised. However, in the case of methylphenidate, there are two stereogenic centres. While one centre is similarly benzylic and can be epimerised as indicated in US-A-2957880, that converts the material into a mixture of two diastereoisomers and not into the racemate that is required for recycling.
30

Summary of the Invention

35 [0007] This invention is based on the discovery of methods to effect racemisation of both chiral centres of methylphenidate. This process gives an optically inactive mixture of stereoisomers in which equilibrium may favour the *threo* isomer; the result is that undesired enantiomer is converted predominantly into the racemate of the *threo* isomer which can then be reintroduced into the resolution. The overall process of a combination of resolution and racemisation that may allow complete conversion into the required isomer is outlined in Scheme 1. The *erythro* isomer that may remain after the racemisation can be separated by conventional methods such as crystallisation at this stage and subjected further to the epimerisation conditions defined below. Alternatively, it can be recycled after passage through resolution of the *threo* isomer.
40
45
50
55



Scheme 1

Description of the Invention

[0008] In Scheme 1, the group X may be the $-CO_2Me$ function of methylphenidate. Resolution of this compound may be carried out by generally known procedures, e.g. by formation of a diastereoisomeric salt with a chiral acid. Alternatively, the resolution may be a biotransformation that modifies the group X in one enantiomer so that the enantiomers (of different compounds) are then readily separated.

[0009] This invention includes the means to effect racemisation at both stereogenic centres. It has been discovered that such racemisation can be carried out by way of activation at the piperidine nitrogen, which probably promotes a fragmentation of the ring, although the exact mechanism has not been ascertained. The putative olefinic intermediate has no chirality and recloses to a racemic mixture.

[0010] There are various ways in which the nitrogen may be activated, to promote the elimination-addition mechanism. One approach is treatment with an acid, for example a carboxylic acid, at a sufficiently high temperature, such as heating with propionic acid, e.g. under reflux. This reaction is suitably conducted in an inert solvent such as toluene. The racemisation can optionally be accelerated by the judicious addition of amounts of additives such as water or inorganic salts that will favour the charge separation in the transition state of the elimination. This reaction may also be promoted by the addition of an aldehyde or ketone (e.g. butyraldehyde or 2-cyclohexen-1-one).

[0011] As indicated above, conditions are known that will epimerise *erythro*-ritalinic acid at the benzylic centre only. On the basis of the evidence herein, it will readily be apparent to the man of ordinary skill in the art that conditions can be adopted, in order to give all 4 stereoisomers of methylphenidate, by racemisation at both chiral centres.

[0012] Following racemisation, and prior to resolution, it is necessary to enrich the mixture in the *threo* enantiomers. For example, the racemic methylphenidate is hydrolysed, e.g. using base such as alkali metal hydroxide. This can be done such that there is also epimerisation. Work-up with acid gives predominantly *threo* ritalinic acid ($X = CO_2H$), which can be esterified, e.g. by reaction with methanol, to give the appropriate substrate for resolution. Alternatively, the *erythro* isomers can be separated by precipitation, and then subjected to sequential epimerisation, esterification and resolution.

[0013] The following experiment was conducted in order to illustrate the feasibility of racemisation.

[0014] Propionic acid (2 ml) was added to a solution of *d-threo*-methylphenidate (5 g) in toluene (25 ml), and the solution was heated under reflux for 4 hours. The mixture was then cooled to ambient temperature, and was rinsed with dilute sodium carbonate and then with water. The organic phase was separated and dried with magnesium sulphate and evaporated under reduced pressure. The resulting oil (4.3 g) was analysed by chiral HPLC which indicated the presence of all 4 stereoisomers of methylphenidate in roughly equal proportions.

[0015] In order to preparing *d-threo*-methylphenidate by an efficient recycling process, the following protocol is adopted:

- 1) Resolve *dl-threo*-methylphenidate by the procedure described in the Example of PCT/GB97/00185.
- 2) Racemise the residual *l-threo*-methylphenidate by the procedure described in the experiment above.
- 3) Hydrolyse the resultant racemic methylphenidate using 50% KOH and heating at reflux.
- 4) Esterify the resultant mixture of enantiomers, enriched in *dl-threo*-ritalinic acid, by reaction with MeOH and HCl.

5) Isolate the free base and recrystallise, to obtain essentially pure *dl-threo*-methylphenidate, suitable as a feed-stock for resolution into constituent enantiomers.

5 Claims

1. A process for obtaining a single enantiomer, *d* or *l*, of *threo*-methylphenidate, which comprises resolution of a mixture of the enantiomers; racemisation of the unwanted enantiomer, to give a mixture of all four stereoisomers; and separation of the *erythro* stereoisomers, to leave the said mixture of enantiomers for resolution.
2. A process according to claim 1, wherein the single enantiomer obtained is the *d-threo* isomer, i.e. the isomer of (*R,R*) absolute configuration.
3. A process according to claim 1 or claim 2, wherein the racemisation comprises heating the unwanted enantiomer with a carboxylic acid.
4. A process according to any preceding claim, wherein the separation is conducted following hydrolysis of the mixture of stereoisomers, to give ritalinic acid, and before or after re-esterification of the acid.
5. A process according to claim 4, which additionally comprises equilibrating the product of hydrolysis such that the *threo* diastereoisomer is preferentially obtained.
6. A process according to any preceding claim, wherein the resolution is conducted using a chiral acid.
7. A process according to claim 6, wherein the acid is *O,O'*-diaroyltartaric acid.

Patentansprüche

1. Verfahren zum Erhalten eines einzelnen *d*- oder *l*-Enantiomers von *threo*-Methylphenidat, welches die Auftrennung einer Mischung der Enantiomere, Racemisierung des unerwünschten Enantiomers, um eine Mischung aller vier Stereoisomere zu ergeben, und die Abtrennung der *erythro*-Stereoisomere, um die genannte Mischung von Enantiomeren für die Auftrennung zurückzulassen, umfasst.
2. Verfahren nach Anspruch 1, worin das erhaltene einzelne Enantiomer das *d-threo*-Isomer ist, d.h., das Isomer der absoluten Konfiguration (*R,R*).
3. Verfahren nach Anspruch 1 oder Anspruch 2, worin die Racemisierung die Erwärmung des unerwünschten Enantiomers mit einer Carbonsäure umfasst.
4. Verfahren nach irgendeinem der vorhergehenden Ansprüche, worin die Abtrennung nach der Hydrolyse der Mischung von Stereoisomeren, um Ritalinsäure zu ergeben, und vor oder nach der erneuten Veresterung der Säure durchgeführt wird.
5. Verfahren nach Anspruch 4, welches zusätzlich die Gleichgewichtseinstellung des Hydrolyseprodukts umfasst, so dass vorzugsweise das *threo*-Diastereoisomer erhalten wird.
6. Verfahren nach irgendeinem der vorhergehenden Ansprüche, worin die Auftrennung unter Verwendung einer chiralen Säure durchgeführt wird.
7. Verfahren nach Anspruch 6, worin die Säure *O,O'*-Diaroylweinsäure ist.

Revendications

1. Procédé pour obtenir un énantiomère unique, *d* ou *l*, du méthylphénidate *thréo*, qui comprend la résolution d'un mélange des énantiomères; la racémisation de l'énantiomère non désiré, pour donner un mélange de tous les quatre stéréoisomères; et la séparation des stéréoisomères *érythro*, pour conserver ledit mélange d'énantiomères

pour résolution.

2. Procédé selon la revendication 1, dans lequel l'énantiomère unique obtenu est l'isomère *d-thréo*, c'est-à-dire l'isomère de configuration absolue (*R,R*).

5

3. Procédé selon la revendication 1 ou la revendication 2, dans lequel la racémisation comprend le chauffage de l'énantiomère non désiré avec de l'acide carboxylique.

10

4. Procédé selon l'une quelconque des revendications précédentes, dans lequel la séparation est conduite à la suite de l'hydrolyse du mélange de stéréoisomères, pour donner de l'acide ritalinique, et avant ou après réestérification de l'acide.

15

5. Procédé selon la revendication 4, qui comprend en plus l'équilibrage du produit d'hydrolyse de sorte que le diastéréoisomère *thréo* est obtenu de manière préférentielle.

6. Procédé selon l'une quelconque des revendications précédentes, dans lequel la résolution est conduite en utilisant un acide chiral.

20

7. Procédé selon la revendication 6, dans lequel l'acide est l'acide *O,O'*-diaroyltartrique.

25

30

35

40

45

50

55